#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4 .
1-1	0-1	4	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Materials and Methods
2-1	4-13	Materials	substance	new	_	_
2-2	14-17	and	_	_	_	_
2-3	18-25	Methods	abstract	new	_	_

#Text=A search was performed of regulatory and scientific literature to identify sources of clinical data to be used to compare the efficacy and safety of BRAFi/MEKi combination therapies for the treatment of BRAF -mutant metastatic melanoma .
3-1	26-27	A	event[4]	new[4]	coref	4-5[18_4]
3-2	28-34	search	event[4]	new[4]	_	_
3-3	35-38	was	_	_	_	_
3-4	39-48	performed	_	_	_	_
3-5	49-51	of	_	_	_	_
3-6	52-62	regulatory	abstract[5]	new[5]	coref	4-6[0_5]
3-7	63-66	and	abstract[5]	new[5]	_	_
3-8	67-77	scientific	abstract[5]	new[5]	_	_
3-9	78-88	literature	abstract[5]	new[5]	_	_
3-10	89-91	to	_	_	_	_
3-11	92-100	identify	_	_	_	_
3-12	101-108	sources	abstract[6]	new[6]	_	_
3-13	109-111	of	abstract[6]	new[6]	_	_
3-14	112-120	clinical	abstract[6]|abstract[7]	new[6]|new[7]	coref	6-37[83_7]
3-15	121-125	data	abstract[6]|abstract[7]	new[6]|new[7]	_	_
3-16	126-128	to	_	_	_	_
3-17	129-131	be	_	_	_	_
3-18	132-136	used	_	_	_	_
3-19	137-139	to	_	_	_	_
3-20	140-147	compare	_	_	_	_
3-21	148-151	the	abstract[8]	new[8]	coref	7-20[0_8]
3-22	152-160	efficacy	abstract[8]	new[8]	_	_
3-23	161-164	and	_	_	_	_
3-24	165-171	safety	abstract[9]	new[9]	coref	15-2[0_9]
3-25	172-174	of	abstract[9]	new[9]	_	_
3-26	175-185	BRAFi/MEKi	abstract[9]|time	new[9]|new	_	_
3-27	186-197	combination	abstract|substance[12]	new|new[12]	coref|coref	20-10[238_0]|20-10[238_0]
3-28	198-207	therapies	substance[12]	new[12]	_	_
3-29	208-211	for	substance[12]	new[12]	_	_
3-30	212-215	the	substance[12]|abstract[13]	new[12]|new[13]	_	_
3-31	216-225	treatment	substance[12]|abstract[13]	new[12]|new[13]	_	_
3-32	226-228	of	substance[12]|abstract[13]	new[12]|new[13]	_	_
3-33	229-233	BRAF	substance[12]|abstract[13]|abstract|abstract[15]	new[12]|new[13]|new|new[15]	coref|coref|coref|coref	5-26[33_0]|5-28[34_15]|5-26[33_0]|5-28[34_15]
3-34	234-241	-mutant	substance[12]|abstract[13]|abstract[15]	new[12]|new[13]|new[15]	_	_
3-35	242-252	metastatic	substance[12]|abstract[13]|abstract[15]	new[12]|new[13]|new[15]	_	_
3-36	253-261	melanoma	substance[12]|abstract[13]|abstract[15]	new[12]|new[13]|new[15]	_	_
3-37	262-263	.	_	_	_	_

#Text=The full details of the literature search are outlined in Table S4 .
4-1	264-267	The	abstract[16]	new[16]	_	_
4-2	268-272	full	abstract[16]	new[16]	_	_
4-3	273-280	details	abstract[16]	new[16]	_	_
4-4	281-283	of	abstract[16]	new[16]	_	_
4-5	284-287	the	abstract[16]|event[18]	new[16]|giv[18]	coref	7-9[87_18]
4-6	288-298	literature	abstract[16]|abstract|event[18]	new[16]|giv|giv[18]	coref	7-11
4-7	299-305	search	abstract[16]|event[18]	new[16]|giv[18]	_	_
4-8	306-309	are	_	_	_	_
4-9	310-318	outlined	_	_	_	_
4-10	319-321	in	_	_	_	_
4-11	322-327	Table	abstract|object[20]	new|new[20]	coref|coref	9-15[106_0]|9-15[106_0]
4-12	328-330	S4	object[20]	new[20]	_	_
4-13	331-332	.	_	_	_	_

#Text=Four phase III studies were identified : coBRIM , a phase III trial of cobimetinib plus vemurafenib versus vemurafenib monotherapy in previously untreated patients with advanced BRAF -mutant melanoma ; COMBI-d , a phase III trial of dabrafenib and trametinib versus dabrafenib monotherapy in previously untreated patients with unresectable stage IIIC or stage IV melanoma with a BRAF V600E or V600K mutation ; COMBI-v , a phase III trial of dabrafenib plus trametinib versus vemurafenib monotherapy in previously untreated patients with unresectable stage IIIC or IV melanoma with BRAF mutation ; and COLUMBUS Part 1 , a phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib monotherapy in patients with BRAF -mutant melanoma .
5-1	333-337	Four	abstract[21]	new[21]	_	_
5-2	338-343	phase	abstract[21]	new[21]	_	_
5-3	344-347	III	event[22]	new[22]	coref	6-3[73_22]
5-4	348-355	studies	event[22]	new[22]	_	_
5-5	356-360	were	_	_	_	_
5-6	361-371	identified	_	_	_	_
5-7	372-373	:	_	_	_	_
5-8	374-380	coBRIM	organization|abstract[24]	new|new[24]	coref|coref|coref|coref	6-7|11-6[122_24]|6-7|11-6[122_24]
5-9	381-382	,	abstract[24]	new[24]	_	_
5-10	383-384	a	abstract[24]|abstract[25]	new[24]|new[25]	coref	5-33[36_25]
5-11	385-390	phase	abstract[24]|abstract[25]	new[24]|new[25]	_	_
5-12	391-394	III	abstract[24]|abstract[25]	new[24]|new[25]	_	_
5-13	395-400	trial	abstract[24]|abstract[26]	new[24]|new[26]	_	_
5-14	401-403	of	abstract[24]|abstract[26]	new[24]|new[26]	_	_
5-15	404-415	cobimetinib	abstract[24]|abstract[26]|abstract|abstract[28]	new[24]|new[26]|new|new[28]	coref|coref|coref|coref	10-21|21-2[242_28]|10-21|21-2[242_28]
5-16	416-420	plus	abstract[24]|abstract[26]|abstract[28]	new[24]|new[26]|new[28]	_	_
5-17	421-432	vemurafenib	abstract[24]|abstract[26]|abstract[28]|abstract[29]	new[24]|new[26]|new[28]|new[29]	coref	5-75[0_29]
5-18	433-439	versus	abstract[24]|abstract[26]|abstract[28]|abstract[29]	new[24]|new[26]|new[28]|new[29]	_	_
5-19	440-451	vemurafenib	abstract[24]|abstract[26]|abstract[28]|abstract[29]|object|abstract[31]	new[24]|new[26]|new[28]|new[29]|new|new[31]	coref|coref	5-75[55_31]|5-75[55_31]
5-20	452-463	monotherapy	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]	new[24]|new[26]|new[28]|new[29]|new[31]	_	_
5-21	464-466	in	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]	new[24]|new[26]|new[28]|new[29]|new[31]	_	_
5-22	467-477	previously	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]	_	_
5-23	478-487	untreated	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]	_	_
5-24	488-496	patients	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]	_	_
5-25	497-501	with	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]	_	_
5-26	502-510	advanced	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[33]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|giv[33]	coref	5-58[0_33]
5-27	511-515	BRAF	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[33]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|giv[33]	_	_
5-28	516-523	-mutant	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[34]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|giv[34]	coref	5-54[47_34]
5-29	524-532	melanoma	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[34]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|giv[34]	_	_
5-30	533-534	;	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]	_	_
5-31	535-542	COMBI-d	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|organization	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new	coref	7-2[85_0]
5-32	543-544	,	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]	_	_
5-33	545-546	a	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[36]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|giv[36]	_	_
5-34	547-552	phase	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[36]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|giv[36]	_	_
5-35	553-556	III	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]	_	_
5-36	557-562	trial	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]	_	_
5-37	563-565	of	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]	_	_
5-38	566-576	dabrafenib	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new	coref	5-42
5-39	577-580	and	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]	_	_
5-40	581-591	trametinib	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract[39]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new[39]	coref	5-73[0_39]
5-41	592-598	versus	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract[39]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new[39]	_	_
5-42	599-609	dabrafenib	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract[39]|object|object[41]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new[39]|giv|new[41]	coref|coref	5-71|5-71
5-43	610-621	monotherapy	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract[39]|object[41]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new[39]|new[41]	_	_
5-44	622-624	in	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract[39]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new[39]	_	_
5-45	625-635	previously	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract[39]|person[42]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new[39]|new[42]	coref	5-78[56_42]
5-46	636-645	untreated	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract[39]|person[42]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new[39]|new[42]	_	_
5-47	646-654	patients	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract[39]|person[42]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new[39]|new[42]	_	_
5-48	655-659	with	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract[39]|person[42]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new[39]|new[42]	_	_
5-49	660-672	unresectable	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract[39]|person[42]|abstract[43]|abstract[44]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new[39]|new[42]|new[43]|new[44]	coref|coref	9-6[103_44]|9-6[103_44]
5-50	673-678	stage	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract[39]|person[42]|abstract[43]|abstract[44]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new[39]|new[42]|new[43]|new[44]	_	_
5-51	679-683	IIIC	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract[39]|person[42]|abstract[43]|abstract[44]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new[39]|new[42]|new[43]|new[44]	_	_
5-52	684-686	or	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract[39]|person[42]|abstract[44]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new[39]|new[42]|new[44]	_	_
5-53	687-692	stage	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract[39]|person[42]|abstract[44]|abstract	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new[39]|new[42]|new[44]|new	coref	5-82[57_0]
5-54	693-695	IV	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract[39]|person[42]|abstract[44]|person|abstract[47]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new[39]|new[42]|new[44]|new|giv[47]	coref|coref|coref|coref	5-86|5-86[60_47]|5-86|5-86[60_47]
5-55	696-704	melanoma	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract[39]|person[42]|abstract[44]|abstract[47]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new[39]|new[42]|new[44]|giv[47]	_	_
5-56	705-709	with	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract[39]|person[42]|abstract[44]|abstract[47]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new[39]|new[42]|new[44]|giv[47]	_	_
5-57	710-711	a	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract[39]|person[42]|abstract[44]|abstract[47]|abstract[49]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new[39]|new[42]|new[44]|giv[47]|new[49]	_	_
5-58	712-716	BRAF	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract[39]|person[42]|abstract[44]|abstract[47]|abstract|abstract[49]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new[39]|new[42]|new[44]|giv[47]|giv|new[49]	_	_
5-59	717-722	V600E	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract[39]|person[42]|abstract[44]|abstract[47]|abstract[49]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new[39]|new[42]|new[44]|giv[47]|new[49]	_	_
5-60	723-725	or	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract[39]|person[42]|abstract[44]|abstract[47]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new[39]|new[42]|new[44]|giv[47]	_	_
5-61	726-731	V600K	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract[39]|person[42]|abstract[44]|abstract[47]|abstract[50]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new[39]|new[42]|new[44]|giv[47]|new[50]	coref	5-89[62_50]
5-62	732-740	mutation	abstract[24]|abstract[26]|abstract[28]|abstract[29]|abstract[31]|person[32]|abstract[37]|abstract[39]|person[42]|abstract[44]|abstract[47]|abstract[50]	new[24]|new[26]|new[28]|new[29]|new[31]|new[32]|new[37]|new[39]|new[42]|new[44]|giv[47]|new[50]	_	_
5-63	741-742	;	_	_	_	_
5-64	743-750	COMBI-v	_	_	_	_
5-65	751-752	,	_	_	_	_
5-66	753-754	a	_	_	_	_
5-67	755-760	phase	_	_	_	_
5-68	761-764	III	abstract[51]	new[51]	_	_
5-69	765-770	trial	abstract[51]	new[51]	_	_
5-70	771-773	of	abstract[51]	new[51]	_	_
5-71	774-784	dabrafenib	abstract[51]|abstract	new[51]|giv	coref	10-25
5-72	785-789	plus	abstract[51]	new[51]	_	_
5-73	790-800	trametinib	abstract[51]|abstract	new[51]|giv	coref	10-27
5-74	801-807	versus	abstract[51]	new[51]	_	_
5-75	808-819	vemurafenib	abstract[51]|abstract|abstract[55]	new[51]|giv|giv[55]	coref|coref|coref|coref	5-106|5-108[68_55]|5-106|5-108[68_55]
5-76	820-831	monotherapy	abstract[51]|abstract[55]	new[51]|giv[55]	_	_
5-77	832-834	in	abstract[51]|abstract[55]	new[51]|giv[55]	_	_
5-78	835-845	previously	abstract[51]|abstract[55]|person[56]	new[51]|giv[55]|giv[56]	coref	5-111[69_56]
5-79	846-855	untreated	abstract[51]|abstract[55]|person[56]	new[51]|giv[55]|giv[56]	_	_
5-80	856-864	patients	abstract[51]|abstract[55]|person[56]	new[51]|giv[55]|giv[56]	_	_
5-81	865-869	with	abstract[51]|abstract[55]|person[56]	new[51]|giv[55]|giv[56]	_	_
5-82	870-882	unresectable	abstract[51]|abstract[55]|person[56]|abstract[57]|abstract[58]	new[51]|giv[55]|giv[56]|giv[57]|new[58]	coref|coref	9-6[104_58]|9-6[104_58]
5-83	883-888	stage	abstract[51]|abstract[55]|person[56]|abstract[57]|abstract[58]	new[51]|giv[55]|giv[56]|giv[57]|new[58]	_	_
5-84	889-893	IIIC	abstract[51]|abstract[55]|person[56]|abstract[57]|abstract[58]	new[51]|giv[55]|giv[56]|giv[57]|new[58]	_	_
5-85	894-896	or	abstract[51]|abstract[55]|person[56]|abstract[58]	new[51]|giv[55]|giv[56]|new[58]	_	_
5-86	897-899	IV	abstract[51]|abstract[55]|person[56]|abstract[58]|person|abstract[60]	new[51]|giv[55]|giv[56]|new[58]|giv|giv[60]	coref|coref	5-113[71_60]|5-113[71_60]
5-87	900-908	melanoma	abstract[51]|abstract[55]|person[56]|abstract[58]|abstract[60]	new[51]|giv[55]|giv[56]|new[58]|giv[60]	_	_
5-88	909-913	with	abstract[51]|abstract[55]|person[56]|abstract[58]|abstract[60]	new[51]|giv[55]|giv[56]|new[58]|giv[60]	_	_
5-89	914-918	BRAF	abstract[51]|abstract[55]|person[56]|abstract[58]|abstract[60]|person|abstract[62]	new[51]|giv[55]|giv[56]|new[58]|giv[60]|new|giv[62]	coref|coref	5-113|5-113
5-90	919-927	mutation	abstract[51]|abstract[55]|person[56]|abstract[58]|abstract[60]|abstract[62]	new[51]|giv[55]|giv[56]|new[58]|giv[60]|giv[62]	_	_
5-91	928-929	;	abstract[51]|abstract[55]|person[56]|abstract[58]|abstract[60]	new[51]|giv[55]|giv[56]|new[58]|giv[60]	_	_
5-92	930-933	and	abstract[51]|abstract[55]|person[56]|abstract[58]|abstract[60]	new[51]|giv[55]|giv[56]|new[58]|giv[60]	_	_
5-93	934-942	COLUMBUS	abstract[51]|abstract[55]|person[56]|abstract[58]|abstract[60]|abstract[63]	new[51]|giv[55]|giv[56]|new[58]|giv[60]|new[63]	appos	5-97[64_63]
5-94	943-947	Part	abstract[51]|abstract[55]|person[56]|abstract[58]|abstract[60]|abstract[63]	new[51]|giv[55]|giv[56]|new[58]|giv[60]|new[63]	_	_
5-95	948-949	1	abstract[51]|abstract[55]|person[56]|abstract[58]|abstract[60]|abstract[63]	new[51]|giv[55]|giv[56]|new[58]|giv[60]|new[63]	_	_
5-96	950-951	,	_	_	_	_
5-97	952-953	a	abstract[64]	giv[64]	coref	6-12[77_64]
5-98	954-959	phase	abstract[64]	giv[64]	_	_
5-99	960-963	III	abstract[64]|abstract[65]	giv[64]|new[65]	coref	12-5[152_65]
5-100	964-969	trial	abstract[64]|abstract[65]	giv[64]|new[65]	_	_
5-101	970-972	of	abstract[64]|abstract[65]	giv[64]|new[65]	_	_
5-102	973-984	encorafenib	abstract[64]|abstract[65]	giv[64]|new[65]	_	_
5-103	985-989	plus	abstract[64]|abstract[65]	giv[64]|new[65]	_	_
5-104	990-1001	binimetinib	abstract[64]|abstract[65]	giv[64]|new[65]	_	_
5-105	1002-1008	versus	abstract[64]|abstract[65]	giv[64]|new[65]	_	_
5-106	1009-1020	vemurafenib	abstract[64]|abstract[65]|abstract	giv[64]|new[65]|giv	coref	6-18
5-107	1021-1023	or	abstract[64]	giv[64]	_	_
5-108	1024-1035	encorafenib	abstract[64]|abstract|abstract[68]	giv[64]|new|giv[68]	coref|coref	10-29|10-29
5-109	1036-1047	monotherapy	abstract[64]|abstract[68]	giv[64]|giv[68]	_	_
5-110	1048-1050	in	abstract[64]|abstract[68]	giv[64]|giv[68]	_	_
5-111	1051-1059	patients	abstract[64]|abstract[68]|person[69]	giv[64]|giv[68]|giv[69]	_	_
5-112	1060-1064	with	abstract[64]|abstract[68]|person[69]	giv[64]|giv[68]|giv[69]	_	_
5-113	1065-1069	BRAF	abstract[64]|abstract[68]|person[69]|person|abstract[71]	giv[64]|giv[68]|giv[69]|giv|giv[71]	_	_
5-114	1070-1077	-mutant	abstract[64]|abstract[68]|person[69]|abstract[71]	giv[64]|giv[68]|giv[69]|giv[71]	_	_
5-115	1078-1086	melanoma	abstract[64]|abstract[68]|person[69]|abstract[71]	giv[64]|giv[68]|giv[69]|giv[71]	_	_
5-116	1087-1088	.	_	_	_	_

#Text=Three of the identified studies ( coBRIM , COMBI-v , and COLUMBUS Part 1 ) , had vemurafenib 960 mg twice daily ( BID ) as a control arm , and were the chief sources of data for the comparisons presented here .
6-1	1089-1094	Three	quantity[72]	new[72]	_	_
6-2	1095-1097	of	quantity[72]	new[72]	_	_
6-3	1098-1101	the	quantity[72]|event[73]	new[72]|giv[73]	appos	6-7[75_73]
6-4	1102-1112	identified	quantity[72]|event[73]	new[72]|giv[73]	_	_
6-5	1113-1120	studies	quantity[72]|event[73]	new[72]|giv[73]	_	_
6-6	1121-1122	(	_	_	_	_
6-7	1123-1129	coBRIM	object|event[75]	giv|giv[75]	coref|coref|coref|coref	11-6|14-8[175_75]|11-6|14-8[175_75]
6-8	1130-1131	,	event[75]	giv[75]	_	_
6-9	1132-1139	COMBI-v	event[75]|organization	giv[75]|new	coref	8-19
6-10	1140-1141	,	event[75]	giv[75]	_	_
6-11	1142-1145	and	event[75]	giv[75]	_	_
6-12	1146-1154	COLUMBUS	event[75]|abstract[77]	giv[75]|giv[77]	ana	7-14[0_77]
6-13	1155-1159	Part	event[75]|abstract[77]	giv[75]|giv[77]	_	_
6-14	1160-1161	1	event[75]|abstract[77]	giv[75]|giv[77]	_	_
6-15	1162-1163	)	_	_	_	_
6-16	1164-1165	,	_	_	_	_
6-17	1166-1169	had	_	_	_	_
6-18	1170-1181	vemurafenib	abstract|substance[79]	giv|new[79]	coref|coref	7-32|7-32
6-19	1182-1185	960	substance[79]	new[79]	_	_
6-20	1186-1188	mg	substance[79]	new[79]	_	_
6-21	1189-1194	twice	_	_	_	_
6-22	1195-1200	daily	_	_	_	_
6-23	1201-1202	(	_	_	_	_
6-24	1203-1206	BID	quantity	new	_	_
6-25	1207-1208	)	_	_	_	_
6-26	1209-1211	as	_	_	_	_
6-27	1212-1213	a	_	_	_	_
6-28	1214-1221	control	abstract	new	coref	7-33
6-29	1222-1225	arm	_	_	_	_
6-30	1226-1227	,	_	_	_	_
6-31	1228-1231	and	_	_	_	_
6-32	1232-1236	were	_	_	_	_
6-33	1237-1240	the	abstract[82]	new[82]	coref	11-1[120_82]
6-34	1241-1246	chief	abstract[82]	new[82]	_	_
6-35	1247-1254	sources	abstract[82]	new[82]	_	_
6-36	1255-1257	of	abstract[82]	new[82]	_	_
6-37	1258-1262	data	abstract[82]|abstract[83]	new[82]|giv[83]	coref	10-34[118_83]
6-38	1263-1266	for	abstract[82]|abstract[83]	new[82]|giv[83]	_	_
6-39	1267-1270	the	abstract[82]|abstract[83]|abstract[84]	new[82]|giv[83]|new[84]	coref	15-1[183_84]
6-40	1271-1282	comparisons	abstract[82]|abstract[83]|abstract[84]	new[82]|giv[83]|new[84]	_	_
6-41	1283-1292	presented	_	_	_	_
6-42	1293-1297	here	_	_	_	_
6-43	1298-1299	.	_	_	_	_

#Text=Although the COMBI-d was identified as part of the initial literature search , it was not included in the efficacy comparison of the cross-trial comparison due to the lack of a vemurafenib control arm .
7-1	1300-1308	Although	_	_	_	_
7-2	1309-1312	the	organization[85]	giv[85]	coref	8-12[0_85]
7-3	1313-1320	COMBI-d	organization[85]	giv[85]	_	_
7-4	1321-1324	was	_	_	_	_
7-5	1325-1335	identified	_	_	_	_
7-6	1336-1338	as	_	_	_	_
7-7	1339-1343	part	_	_	_	_
7-8	1344-1346	of	_	_	_	_
7-9	1347-1350	the	event[87]	giv[87]	_	_
7-10	1351-1358	initial	event[87]	giv[87]	_	_
7-11	1359-1369	literature	abstract|event[87]	giv|giv[87]	_	_
7-12	1370-1376	search	event[87]	giv[87]	_	_
7-13	1377-1378	,	_	_	_	_
7-14	1379-1381	it	abstract	giv	_	_
7-15	1382-1385	was	_	_	_	_
7-16	1386-1389	not	_	_	_	_
7-17	1390-1398	included	_	_	_	_
7-18	1399-1401	in	_	_	_	_
7-19	1402-1405	the	abstract[90]	new[90]	coref	10-7[108_90]
7-20	1406-1414	efficacy	abstract|abstract[90]	giv|new[90]	coref	13-2
7-21	1415-1425	comparison	abstract[90]	new[90]	_	_
7-22	1426-1428	of	abstract[90]	new[90]	_	_
7-23	1429-1432	the	abstract[90]|event[91]	new[90]|new[91]	_	_
7-24	1433-1444	cross-trial	abstract[90]|event[91]	new[90]|new[91]	_	_
7-25	1445-1455	comparison	abstract[90]|event[91]	new[90]|new[91]	_	_
7-26	1456-1459	due	_	_	_	_
7-27	1460-1462	to	_	_	_	_
7-28	1463-1466	the	abstract[92]	new[92]	ana	8-1[0_92]
7-29	1467-1471	lack	abstract[92]	new[92]	_	_
7-30	1472-1474	of	abstract[92]	new[92]	_	_
7-31	1475-1476	a	abstract[92]|object[95]	new[92]|new[95]	_	_
7-32	1477-1488	vemurafenib	abstract[92]|abstract|object[95]	new[92]|giv|new[95]	coref	10-23
7-33	1489-1496	control	abstract[92]|abstract|object[95]	new[92]|giv|new[95]	_	_
7-34	1497-1500	arm	abstract[92]|object[95]	new[92]|new[95]	_	_
7-35	1501-1502	.	_	_	_	_

#Text=It should be noted , however , that the outcomes in COMBI-d were substantially similar to those in COMBI-v .
8-1	1503-1505	It	abstract	giv	ana	8-17[99_0]
8-2	1506-1512	should	_	_	_	_
8-3	1513-1515	be	_	_	_	_
8-4	1516-1521	noted	_	_	_	_
8-5	1522-1523	,	_	_	_	_
8-6	1524-1531	however	_	_	_	_
8-7	1532-1533	,	_	_	_	_
8-8	1534-1538	that	_	_	_	_
8-9	1539-1542	the	abstract[97]	new[97]	coref	13-1[160_97]
8-10	1543-1551	outcomes	abstract[97]	new[97]	_	_
8-11	1552-1554	in	abstract[97]	new[97]	_	_
8-12	1555-1562	COMBI-d	abstract[97]|abstract	new[97]|giv	coref	20-16
8-13	1563-1567	were	_	_	_	_
8-14	1568-1581	substantially	_	_	_	_
8-15	1582-1589	similar	_	_	_	_
8-16	1590-1592	to	_	_	_	_
8-17	1593-1598	those	abstract[99]	giv[99]	_	_
8-18	1599-1601	in	abstract[99]	giv[99]	_	_
8-19	1602-1609	COMBI-v	abstract[99]|abstract	giv[99]|giv	coref	11-8
8-20	1610-1611	.	_	_	_	_

#Text=The key design features of the three included phase III trials are summarized in Table 5 .
9-1	1612-1615	The	abstract[102]	new[102]	_	_
9-2	1616-1619	key	abstract[102]	new[102]	_	_
9-3	1620-1626	design	abstract|abstract[102]	new|new[102]	_	_
9-4	1627-1635	features	abstract[102]	new[102]	_	_
9-5	1636-1638	of	abstract[102]	new[102]	_	_
9-6	1639-1642	the	abstract[102]|abstract[103]|abstract[104]	new[102]|giv[103]|giv[104]	_	_
9-7	1643-1648	three	abstract[102]|abstract[103]|abstract[104]	new[102]|giv[103]|giv[104]	_	_
9-8	1649-1657	included	abstract[102]|abstract[103]|abstract[104]	new[102]|giv[103]|giv[104]	_	_
9-9	1658-1663	phase	abstract[102]|abstract[103]|abstract[104]	new[102]|giv[103]|giv[104]	_	_
9-10	1664-1667	III	abstract[102]|abstract[104]|abstract[105]	new[102]|giv[104]|new[105]	coref	11-5[124_105]
9-11	1668-1674	trials	abstract[102]|abstract[104]|abstract[105]	new[102]|giv[104]|new[105]	_	_
9-12	1675-1678	are	_	_	_	_
9-13	1679-1689	summarized	_	_	_	_
9-14	1690-1692	in	_	_	_	_
9-15	1693-1698	Table	abstract[106]	giv[106]	coref	11-46[0_106]
9-16	1699-1700	5	abstract[106]	giv[106]	_	_
9-17	1701-1702	.	_	_	_	_

#Text=To assist with the completeness of the cross-trial comparison , medical information requests were made to the registered sponsor of cobimetinib , vemurafenib , dabrafenib , trametinib , encorafenib , or binimetinib if any missing data were identified .
10-1	1703-1705	To	_	_	_	_
10-2	1706-1712	assist	_	_	_	_
10-3	1713-1717	with	_	_	_	_
10-4	1718-1721	the	abstract[107]	new[107]	_	_
10-5	1722-1734	completeness	abstract[107]	new[107]	_	_
10-6	1735-1737	of	abstract[107]	new[107]	_	_
10-7	1738-1741	the	abstract[107]|abstract[108]	new[107]|giv[108]	_	_
10-8	1742-1753	cross-trial	abstract[107]|abstract[108]	new[107]|giv[108]	_	_
10-9	1754-1764	comparison	abstract[107]|abstract[108]	new[107]|giv[108]	_	_
10-10	1765-1766	,	_	_	_	_
10-11	1767-1774	medical	abstract[110]	new[110]	_	_
10-12	1775-1786	information	abstract|abstract[110]	new|new[110]	coref	11-39[138_0]
10-13	1787-1795	requests	abstract[110]	new[110]	_	_
10-14	1796-1800	were	_	_	_	_
10-15	1801-1805	made	_	_	_	_
10-16	1806-1808	to	_	_	_	_
10-17	1809-1812	the	person[111]	new[111]	_	_
10-18	1813-1823	registered	person[111]	new[111]	_	_
10-19	1824-1831	sponsor	person[111]	new[111]	_	_
10-20	1832-1834	of	person[111]	new[111]	_	_
10-21	1835-1846	cobimetinib	person[111]|object	new[111]|giv	coref	21-2[241_0]
10-22	1847-1848	,	person[111]	new[111]	_	_
10-23	1849-1860	vemurafenib	person[111]|abstract	new[111]|giv	coref	21-5
10-24	1861-1862	,	person[111]	new[111]	_	_
10-25	1863-1873	dabrafenib	person[111]|object	new[111]|giv	coref	20-7[237_0]
10-26	1874-1875	,	person[111]	new[111]	_	_
10-27	1876-1886	trametinib	person[111]|abstract	new[111]|giv	_	_
10-28	1887-1888	,	person[111]	new[111]	_	_
10-29	1889-1900	encorafenib	person[111]|substance	new[111]|giv	coref	22-16[251_0]
10-30	1901-1902	,	person[111]	new[111]	_	_
10-31	1903-1905	or	person[111]	new[111]	_	_
10-32	1906-1917	binimetinib	person[111]|object	new[111]|new	coref	22-19
10-33	1918-1920	if	_	_	_	_
10-34	1921-1924	any	abstract[118]	giv[118]	coref	11-16[126_118]
10-35	1925-1932	missing	abstract[118]	giv[118]	_	_
10-36	1933-1937	data	abstract[118]	giv[118]	_	_
10-37	1938-1942	were	_	_	_	_
10-38	1943-1953	identified	_	_	_	_
10-39	1954-1955	.	_	_	_	_

#Text=The data sources for the coBRIM and COMBI-v trials included primary and secondary publications of data , European public assessment reports ( EPAR ) , U.S. Food and Drug Administration ( FDA ) medical review documents , and the current U.S. prescribing information ( see Table S5 , which illustrates the data sources and cutoff dates for COMBI-v , coBRIM , and COLUMBUS trials ) .
11-1	1956-1959	The	abstract[120]	giv[120]	coref	11-51[142_120]
11-2	1960-1964	data	abstract|abstract[120]	new|giv[120]	_	_
11-3	1965-1972	sources	abstract[120]	giv[120]	_	_
11-4	1973-1976	for	abstract[120]	giv[120]	_	_
11-5	1977-1980	the	abstract[120]|abstract[124]	giv[120]|giv[124]	coref	11-63[148_124]
11-6	1981-1987	coBRIM	abstract[120]|organization|abstract[122]|abstract[124]	giv[120]|giv|giv[122]|giv[124]	coref|coref|coref|coref	11-60|18-2[221_122]|11-60|18-2[221_122]
11-7	1988-1991	and	abstract[120]|abstract[122]|abstract[124]	giv[120]|giv[122]|giv[124]	_	_
11-8	1992-1999	COMBI-v	abstract[120]|abstract[122]|event|abstract[124]	giv[120]|giv[122]|giv|giv[124]	coref	11-58
11-9	2000-2006	trials	abstract[120]|abstract[124]	giv[120]|giv[124]	_	_
11-10	2007-2015	included	_	_	_	_
11-11	2016-2023	primary	abstract[125]	new[125]	_	_
11-12	2024-2027	and	abstract[125]	new[125]	_	_
11-13	2028-2037	secondary	abstract[125]	new[125]	_	_
11-14	2038-2050	publications	abstract[125]	new[125]	_	_
11-15	2051-2053	of	abstract[125]	new[125]	_	_
11-16	2054-2058	data	abstract[125]|abstract[126]	new[125]|giv[126]	coref	11-52[0_126]
11-17	2059-2060	,	abstract[125]|abstract[126]	new[125]|giv[126]	_	_
11-18	2061-2069	European	abstract[125]|abstract[126]|abstract[128]	new[125]|giv[126]|new[128]	_	_
11-19	2070-2076	public	abstract[125]|abstract[126]|abstract[128]	new[125]|giv[126]|new[128]	_	_
11-20	2077-2087	assessment	abstract[125]|abstract[126]|abstract|abstract[128]	new[125]|giv[126]|new|new[128]	coref	13-22[170_0]
11-21	2088-2095	reports	abstract[125]|abstract[126]|abstract[128]	new[125]|giv[126]|new[128]	_	_
11-22	2096-2097	(	_	_	_	_
11-23	2098-2102	EPAR	organization	new	_	_
11-24	2103-2104	)	_	_	_	_
11-25	2105-2106	,	_	_	_	_
11-26	2107-2111	U.S.	place|object[131]	new|new[131]	coref|coref	11-41|11-41
11-27	2112-2116	Food	object[131]	new[131]	_	_
11-28	2117-2120	and	_	_	_	_
11-29	2121-2125	Drug	organization[132]	new[132]	appos	11-32[0_132]
11-30	2126-2140	Administration	organization[132]	new[132]	_	_
11-31	2141-2142	(	_	_	_	_
11-32	2143-2146	FDA	organization	giv	_	_
11-33	2147-2148	)	_	_	_	_
11-34	2149-2156	medical	abstract[134]|object[135]	new[134]|new[135]	_	_
11-35	2157-2163	review	abstract[134]|object[135]	new[134]|new[135]	_	_
11-36	2164-2173	documents	object[135]	new[135]	_	_
11-37	2174-2175	,	_	_	_	_
11-38	2176-2179	and	_	_	_	_
11-39	2180-2183	the	abstract[138]	giv[138]	coref	12-13[155_138]
11-40	2184-2191	current	abstract[138]	giv[138]	_	_
11-41	2192-2196	U.S.	place|abstract[138]	giv|giv[138]	coref	12-13
11-42	2197-2208	prescribing	person|abstract[138]	new|giv[138]	_	_
11-43	2209-2220	information	abstract[138]	giv[138]	_	_
11-44	2221-2222	(	_	_	_	_
11-45	2223-2226	see	_	_	_	_
11-46	2227-2232	Table	abstract|object[140]	giv|new[140]	_	_
11-47	2233-2235	S5	object[140]	new[140]	_	_
11-48	2236-2237	,	_	_	_	_
11-49	2238-2243	which	_	_	_	_
11-50	2244-2255	illustrates	_	_	_	_
11-51	2256-2259	the	abstract[142]	giv[142]	coref	12-1[150_142]
11-52	2260-2264	data	abstract|abstract[142]	giv|giv[142]	coref	12-2
11-53	2265-2272	sources	abstract[142]	giv[142]	_	_
11-54	2273-2276	and	abstract[142]	giv[142]	_	_
11-55	2277-2283	cutoff	abstract[142]|abstract|time[144]	giv[142]|new|new[144]	_	_
11-56	2284-2289	dates	abstract[142]|time[144]	giv[142]|new[144]	_	_
11-57	2290-2293	for	abstract[142]|time[144]	giv[142]|new[144]	_	_
11-58	2294-2301	COMBI-v	abstract[142]|time[144]|abstract	giv[142]|new[144]|giv	coref	18-4
11-59	2302-2303	,	abstract[142]|time[144]	giv[142]|new[144]	_	_
11-60	2304-2310	coBRIM	abstract[142]|time[144]|object	giv[142]|new[144]|giv	coref	18-2
11-61	2311-2312	,	abstract[142]|time[144]	giv[142]|new[144]	_	_
11-62	2313-2316	and	abstract[142]|time[144]	giv[142]|new[144]	_	_
11-63	2317-2325	COLUMBUS	abstract[142]|time[144]|place|abstract[148]	giv[142]|new[144]|new|giv[148]	coref|coref|coref|coref	12-6|18-1[223_148]|12-6|18-1[223_148]
11-64	2326-2332	trials	abstract[142]|time[144]|abstract[148]	giv[142]|new[144]|giv[148]	_	_
11-65	2333-2334	)	_	_	_	_
11-66	2335-2336	.	_	_	_	_

#Text=The data sources for the COLUMBUS trial include a primary publication , U.S. prescribing information , and Array BioPharma data on file .
12-1	2337-2340	The	abstract[150]	giv[150]	_	_
12-2	2341-2345	data	abstract|abstract[150]	giv|giv[150]	coref	12-18[157_0]
12-3	2346-2353	sources	abstract[150]	giv[150]	_	_
12-4	2354-2357	for	abstract[150]	giv[150]	_	_
12-5	2358-2361	the	abstract[150]|abstract[152]	giv[150]|giv[152]	coref	18-11[226_152]
12-6	2362-2370	COLUMBUS	abstract[150]|place|abstract[152]	giv[150]|giv|giv[152]	coref	18-12
12-7	2371-2376	trial	abstract[150]|abstract[152]	giv[150]|giv[152]	_	_
12-8	2377-2384	include	_	_	_	_
12-9	2385-2386	a	abstract[153]	new[153]	_	_
12-10	2387-2394	primary	abstract[153]	new[153]	_	_
12-11	2395-2406	publication	abstract[153]	new[153]	_	_
12-12	2407-2408	,	_	_	_	_
12-13	2409-2413	U.S.	place|abstract[155]	giv|giv[155]	coref|coref	19-13|19-13
12-14	2414-2425	prescribing	abstract[155]	giv[155]	_	_
12-15	2426-2437	information	abstract[155]	giv[155]	_	_
12-16	2438-2439	,	_	_	_	_
12-17	2440-2443	and	_	_	_	_
12-18	2444-2449	Array	organization[156]|abstract[157]	new[156]|giv[157]	coref|coref	15-36[193_157]|15-36[193_157]
12-19	2450-2459	BioPharma	organization[156]|abstract[157]	new[156]|giv[157]	_	_
12-20	2460-2464	data	abstract[157]	giv[157]	_	_
12-21	2465-2467	on	abstract[157]	giv[157]	_	_
12-22	2468-2472	file	abstract[157]|object	giv[157]|new	_	_
12-23	2473-2474	.	_	_	_	_

#Text=The efficacy outcomes presented are PFS , objective response rate ( ORR ) , duration of response ( DOR ) per investigator assessment , and OS .
13-1	2475-2478	The	abstract[160]	giv[160]	coref	13-6[161_160]
13-2	2479-2487	efficacy	abstract|abstract[160]	giv|giv[160]	_	_
13-3	2488-2496	outcomes	abstract[160]	giv[160]	_	_
13-4	2497-2506	presented	_	_	_	_
13-5	2507-2510	are	_	_	_	_
13-6	2511-2514	PFS	abstract[161]	giv[161]	_	_
13-7	2515-2516	,	abstract[161]	giv[161]	_	_
13-8	2517-2526	objective	abstract[161]|abstract|abstract[164]	giv[161]|new|new[164]	appos|appos	13-12[0_164]|13-12[0_164]
13-9	2527-2535	response	abstract[161]|event|abstract[164]	giv[161]|new|new[164]	coref	13-17
13-10	2536-2540	rate	abstract[161]|abstract[164]	giv[161]|new[164]	_	_
13-11	2541-2542	(	abstract[161]	giv[161]	_	_
13-12	2543-2546	ORR	abstract[161]|abstract	giv[161]|giv	_	_
13-13	2547-2548	)	abstract[161]	giv[161]	_	_
13-14	2549-2550	,	abstract[161]	giv[161]	_	_
13-15	2551-2559	duration	abstract[161]|abstract[166]	giv[161]|new[166]	_	_
13-16	2560-2562	of	abstract[161]|abstract[166]	giv[161]|new[166]	_	_
13-17	2563-2571	response	abstract[161]|abstract[166]|event	giv[161]|new[166]|giv	appos	13-19
13-18	2572-2573	(	_	_	_	_
13-19	2574-2577	DOR	event	giv	coref	14-4[174_0]
13-20	2578-2579	)	_	_	_	_
13-21	2580-2583	per	_	_	_	_
13-22	2584-2596	investigator	person|abstract[170]	new|giv[170]	coref|coref	14-14[0_170]|14-14[0_170]
13-23	2597-2607	assessment	abstract[170]	giv[170]	_	_
13-24	2608-2609	,	_	_	_	_
13-25	2610-2613	and	_	_	_	_
13-26	2614-2616	OS	abstract	new	_	_
13-27	2617-2618	.	_	_	_	_

#Text=The assessments of the tumor response across the studies were performed using Response Evaluation Criteria in Solid Tumors ( RECIST ) version 1.1 .
14-1	2619-2622	The	abstract[172]	new[172]	_	_
14-2	2623-2634	assessments	abstract[172]	new[172]	_	_
14-3	2635-2637	of	abstract[172]	new[172]	_	_
14-4	2638-2641	the	abstract[172]|event[174]	new[172]|giv[174]	coref	14-13[0_174]
14-5	2642-2647	tumor	abstract[172]|abstract|event[174]	new[172]|new|giv[174]	_	_
14-6	2648-2656	response	abstract[172]|event[174]	new[172]|giv[174]	_	_
14-7	2657-2663	across	abstract[172]|event[174]	new[172]|giv[174]	_	_
14-8	2664-2667	the	abstract[172]|event[174]|event[175]	new[172]|giv[174]|giv[175]	coref	17-1[211_175]
14-9	2668-2675	studies	abstract[172]|event[174]|event[175]	new[172]|giv[174]|giv[175]	_	_
14-10	2676-2680	were	_	_	_	_
14-11	2681-2690	performed	_	_	_	_
14-12	2691-2696	using	_	_	_	_
14-13	2697-2705	Response	event|abstract[178]	giv|new[178]	coref|coref|coref|coref	15-7[184_0]|17-11[215_178]|15-7[184_0]|17-11[215_178]
14-14	2706-2716	Evaluation	abstract|abstract[178]	giv|new[178]	_	_
14-15	2717-2725	Criteria	abstract[178]	new[178]	_	_
14-16	2726-2728	in	abstract[178]	new[178]	_	_
14-17	2729-2734	Solid	abstract[178]|place[179]|abstract[181]	new[178]|new[179]|new[181]	_	_
14-18	2735-2741	Tumors	abstract[178]|place[179]|abstract[181]	new[178]|new[179]|new[181]	_	_
14-19	2742-2743	(	abstract[178]|abstract[181]	new[178]|new[181]	_	_
14-20	2744-2750	RECIST	abstract[178]|abstract|abstract[181]	new[178]|new|new[181]	_	_
14-21	2751-2752	)	abstract[178]|abstract[181]	new[178]|new[181]	_	_
14-22	2753-2760	version	abstract[178]|abstract[181]	new[178]|new[181]	_	_
14-23	2761-2764	1.1	abstract[178]|abstract[181]	new[178]|new[181]	_	_
14-24	2765-2766	.	_	_	_	_

#Text=The safety comparisons were made using the adverse event ( any untoward medical occurrence regardless of causal relationship ) and adverse drug reaction ( noxious and unintended responses with at least a reasonable possibility of a causal relationship ) data .
15-1	2767-2770	The	abstract[183]	giv[183]	_	_
15-2	2771-2777	safety	abstract|abstract[183]	giv|giv[183]	_	_
15-3	2778-2789	comparisons	abstract[183]	giv[183]	_	_
15-4	2790-2794	were	_	_	_	_
15-5	2795-2799	made	_	_	_	_
15-6	2800-2805	using	_	_	_	_
15-7	2806-2809	the	event[184]	giv[184]	coref	16-3[0_184]
15-8	2810-2817	adverse	event[184]	giv[184]	_	_
15-9	2818-2823	event	event[184]	giv[184]	_	_
15-10	2824-2825	(	_	_	_	_
15-11	2826-2829	any	_	_	_	_
15-12	2830-2838	untoward	_	_	_	_
15-13	2839-2846	medical	_	_	_	_
15-14	2847-2857	occurrence	abstract	new	_	_
15-15	2858-2868	regardless	_	_	_	_
15-16	2869-2871	of	_	_	_	_
15-17	2872-2878	causal	abstract[186]	new[186]	coref	15-36[192_186]
15-18	2879-2891	relationship	abstract[186]	new[186]	_	_
15-19	2892-2893	)	_	_	_	_
15-20	2894-2897	and	_	_	_	_
15-21	2898-2905	adverse	event[188]	new[188]	appos	15-24[190_188]
15-22	2906-2910	drug	substance|event[188]	new|new[188]	coref	19-8
15-23	2911-2919	reaction	event[188]	new[188]	_	_
15-24	2920-2921	(	event[190]	giv[190]	_	_
15-25	2922-2929	noxious	abstract[189]|event[190]	new[189]|giv[190]	_	_
15-26	2930-2933	and	abstract[189]|event[190]	new[189]|giv[190]	_	_
15-27	2934-2944	unintended	abstract[189]|event[190]	new[189]|giv[190]	_	_
15-28	2945-2954	responses	abstract[189]|event[190]	new[189]|giv[190]	_	_
15-29	2955-2959	with	event[190]	giv[190]	_	_
15-30	2960-2962	at	event[190]|abstract[191]	giv[190]|new[191]	_	_
15-31	2963-2968	least	event[190]|abstract[191]	giv[190]|new[191]	_	_
15-32	2969-2970	a	event[190]|abstract[191]	giv[190]|new[191]	_	_
15-33	2971-2981	reasonable	event[190]|abstract[191]	giv[190]|new[191]	_	_
15-34	2982-2993	possibility	event[190]|abstract[191]	giv[190]|new[191]	_	_
15-35	2994-2996	of	event[190]|abstract[191]	giv[190]|new[191]	_	_
15-36	2997-2998	a	event[190]|abstract[191]|abstract[192]|abstract[193]	giv[190]|new[191]|giv[192]|giv[193]	coref|coref	16-1[195_193]|16-1[195_193]
15-37	2999-3005	causal	event[190]|abstract[191]|abstract[192]|abstract[193]	giv[190]|new[191]|giv[192]|giv[193]	_	_
15-38	3006-3018	relationship	event[190]|abstract[191]|abstract[192]|abstract[193]	giv[190]|new[191]|giv[192]|giv[193]	_	_
15-39	3019-3020	)	event[190]|abstract[191]|abstract[193]	giv[190]|new[191]|giv[193]	_	_
15-40	3021-3025	data	event[190]|abstract[191]|abstract[193]	giv[190]|new[191]|giv[193]	_	_
15-41	3026-3027	.	_	_	_	_

#Text=The adverse event data included the overall summaries ( comprising all-grade , serious , and grade 3/4 AEs , and AEs leading to death , dose interruption/modification , and discontinuation ) and the incidence of specific all-grade and grade 3/4 AEs by individual preferred terms per the MedDRA dictionary .
16-1	3028-3031	The	abstract[195]	giv[195]	coref	19-5[230_195]
16-2	3032-3039	adverse	abstract[195]	giv[195]	_	_
16-3	3040-3045	event	event|abstract[195]	giv|giv[195]	coref	20-4
16-4	3046-3050	data	abstract[195]	giv[195]	_	_
16-5	3051-3059	included	_	_	_	_
16-6	3060-3063	the	object[196]	new[196]	_	_
16-7	3064-3071	overall	object[196]	new[196]	_	_
16-8	3072-3081	summaries	object[196]	new[196]	_	_
16-9	3082-3083	(	_	_	_	_
16-10	3084-3094	comprising	_	_	_	_
16-11	3095-3104	all-grade	_	_	_	_
16-12	3105-3106	,	_	_	_	_
16-13	3107-3114	serious	_	_	_	_
16-14	3115-3116	,	_	_	_	_
16-15	3117-3120	and	_	_	_	_
16-16	3121-3126	grade	abstract[197]	new[197]	coref	16-39[0_197]
16-17	3127-3130	3/4	abstract[197]|abstract[198]	new[197]|new[198]	coref	16-21[0_198]
16-18	3131-3134	AEs	abstract[197]|abstract[198]	new[197]|new[198]	_	_
16-19	3135-3136	,	_	_	_	_
16-20	3137-3140	and	_	_	_	_
16-21	3141-3144	AEs	abstract	giv	coref	16-40[207_0]
16-22	3145-3152	leading	_	_	_	_
16-23	3153-3155	to	_	_	_	_
16-24	3156-3161	death	event	new	_	_
16-25	3162-3163	,	_	_	_	_
16-26	3164-3168	dose	quantity|abstract[202]	new|new[202]	_	_
16-27	3169-3194	interruption/modification	abstract[202]	new[202]	_	_
16-28	3195-3196	,	_	_	_	_
16-29	3197-3200	and	_	_	_	_
16-30	3201-3216	discontinuation	abstract	new	_	_
16-31	3217-3218	)	_	_	_	_
16-32	3219-3222	and	_	_	_	_
16-33	3223-3226	the	abstract[204]	new[204]	_	_
16-34	3227-3236	incidence	abstract[204]	new[204]	_	_
16-35	3237-3239	of	abstract[204]	new[204]	_	_
16-36	3240-3248	specific	abstract[204]|abstract[205]	new[204]|new[205]	_	_
16-37	3249-3258	all-grade	abstract[204]|abstract[205]	new[204]|new[205]	_	_
16-38	3259-3262	and	abstract[204]	new[204]	_	_
16-39	3263-3268	grade	abstract[204]|abstract	new[204]|giv	_	_
16-40	3269-3272	3/4	abstract[204]|abstract[207]	new[204]|giv[207]	_	_
16-41	3273-3276	AEs	abstract[204]|abstract[207]	new[204]|giv[207]	_	_
16-42	3277-3279	by	abstract[204]	new[204]	_	_
16-43	3280-3290	individual	abstract[204]|abstract[208]	new[204]|new[208]	_	_
16-44	3291-3300	preferred	abstract[204]|abstract[208]	new[204]|new[208]	_	_
16-45	3301-3306	terms	abstract[204]|abstract[208]	new[204]|new[208]	_	_
16-46	3307-3310	per	abstract[204]|abstract[208]	new[204]|new[208]	_	_
16-47	3311-3314	the	abstract[204]|abstract[208]|object[210]	new[204]|new[208]|new[210]	_	_
16-48	3315-3321	MedDRA	abstract[204]|abstract[208]|person|object[210]	new[204]|new[208]|new|new[210]	_	_
16-49	3322-3332	dictionary	abstract[204]|abstract[208]|object[210]	new[204]|new[208]|new[210]	_	_
16-50	3333-3334	.	_	_	_	_

#Text=All studies utilized the National Cancer Institute ( NCI ) Common Terminology Criteria for Adverse Events ( CTCAE ) to assess severity .
17-1	3335-3338	All	event[211]	giv[211]	_	_
17-2	3339-3346	studies	event[211]	giv[211]	_	_
17-3	3347-3355	utilized	_	_	_	_
17-4	3356-3359	the	organization[212]	new[212]	appos	17-9[0_212]
17-5	3360-3368	National	organization[212]	new[212]	_	_
17-6	3369-3375	Cancer	organization[212]	new[212]	_	_
17-7	3376-3385	Institute	organization[212]	new[212]	_	_
17-8	3386-3387	(	_	_	_	_
17-9	3388-3391	NCI	organization	giv	_	_
17-10	3392-3393	)	_	_	_	_
17-11	3394-3400	Common	abstract[215]	giv[215]	_	_
17-12	3401-3412	Terminology	abstract|abstract[215]	new|giv[215]	_	_
17-13	3413-3421	Criteria	abstract[215]	giv[215]	_	_
17-14	3422-3425	for	abstract[215]	giv[215]	_	_
17-15	3426-3433	Adverse	abstract[215]|person|abstract[217]	giv[215]|new|new[217]	appos|appos	17-18[0_217]|17-18[0_217]
17-16	3434-3440	Events	abstract[215]|abstract[217]	giv[215]|new[217]	_	_
17-17	3441-3442	(	_	_	_	_
17-18	3443-3448	CTCAE	abstract	giv	_	_
17-19	3449-3450	)	_	_	_	_
17-20	3451-3453	to	_	_	_	_
17-21	3454-3460	assess	_	_	_	_
17-22	3461-3469	severity	abstract	new	_	_
17-23	3470-3471	.	_	_	_	_

#Text=The coBRIM and COMBI-v trials used version 4.0 , whereas the COLUMBUS trial used version 4.03 .
18-1	3472-3475	The	abstract[223]	giv[223]	_	_
18-2	3476-3482	coBRIM	object|abstract[221]|abstract[223]	giv|giv[221]|giv[223]	coref|coref	21-9|21-9
18-3	3483-3486	and	abstract[221]|abstract[223]	giv[221]|giv[223]	_	_
18-4	3487-3494	COMBI-v	abstract[221]|organization|abstract[223]	giv[221]|giv|giv[223]	_	_
18-5	3495-3501	trials	abstract[223]	giv[223]	_	_
18-6	3502-3506	used	_	_	_	_
18-7	3507-3514	version	abstract[224]	new[224]	coref	18-15[0_224]
18-8	3515-3518	4.0	abstract[224]	new[224]	_	_
18-9	3519-3520	,	_	_	_	_
18-10	3521-3528	whereas	_	_	_	_
18-11	3529-3532	the	abstract[226]	giv[226]	coref	20-15[240_226]
18-12	3533-3541	COLUMBUS	organization|abstract[226]	giv|giv[226]	coref	22-2
18-13	3542-3547	trial	abstract[226]	giv[226]	_	_
18-14	3548-3552	used	_	_	_	_
18-15	3553-3560	version	abstract	giv	_	_
18-16	3561-3565	4.03	quantity	new	_	_
18-17	3566-3567	.	_	_	_	_

#Text=The primary source of data on adverse drug reactions was the available U.S. prescribing information .
19-1	3568-3571	The	abstract[229]	new[229]	coref	19-11[234_229]
19-2	3572-3579	primary	abstract[229]	new[229]	_	_
19-3	3580-3586	source	abstract[229]	new[229]	_	_
19-4	3587-3589	of	abstract[229]	new[229]	_	_
19-5	3590-3594	data	abstract[229]|abstract[230]	new[229]|giv[230]	coref	20-1[236_230]
19-6	3595-3597	on	abstract[229]|abstract[230]	new[229]|giv[230]	_	_
19-7	3598-3605	adverse	abstract[229]|abstract[230]|event[232]	new[229]|giv[230]|new[232]	_	_
19-8	3606-3610	drug	abstract[229]|abstract[230]|substance|event[232]	new[229]|giv[230]|giv|new[232]	_	_
19-9	3611-3620	reactions	abstract[229]|abstract[230]|event[232]	new[229]|giv[230]|new[232]	_	_
19-10	3621-3624	was	_	_	_	_
19-11	3625-3628	the	abstract[234]	giv[234]	coref	22-10[249_234]
19-12	3629-3638	available	abstract[234]	giv[234]	_	_
19-13	3639-3643	U.S.	place|abstract[234]	giv|giv[234]	_	_
19-14	3644-3655	prescribing	abstract[234]	giv[234]	_	_
19-15	3656-3667	information	abstract[234]	giv[234]	_	_
19-16	3668-3669	.	_	_	_	_

#Text=The additional adverse event data for the dabrafenib plus trametinib combination was derived from the COMBI-d trial .
20-1	3670-3673	The	abstract[236]	giv[236]	_	_
20-2	3674-3684	additional	abstract[236]	giv[236]	_	_
20-3	3685-3692	adverse	abstract[236]	giv[236]	_	_
20-4	3693-3698	event	event|abstract[236]	giv|giv[236]	_	_
20-5	3699-3703	data	abstract[236]	giv[236]	_	_
20-6	3704-3707	for	abstract[236]	giv[236]	_	_
20-7	3708-3711	the	abstract[236]|abstract[237]	giv[236]|giv[237]	_	_
20-8	3712-3722	dabrafenib	abstract[236]|abstract[237]	giv[236]|giv[237]	_	_
20-9	3723-3727	plus	abstract[236]	giv[236]	_	_
20-10	3728-3738	trametinib	abstract[236]|abstract[238]	giv[236]|giv[238]	coref	21-5[244_238]
20-11	3739-3750	combination	abstract[236]|abstract[238]	giv[236]|giv[238]	_	_
20-12	3751-3754	was	_	_	_	_
20-13	3755-3762	derived	_	_	_	_
20-14	3763-3767	from	_	_	_	_
20-15	3768-3771	the	abstract[240]	giv[240]	coref	21-8[246_240]
20-16	3772-3779	COMBI-d	abstract|abstract[240]	giv|giv[240]	_	_
20-17	3780-3785	trial	abstract[240]	giv[240]	_	_
20-18	3786-3787	.	_	_	_	_

#Text=For the cobimetinib plus vemurafenib combination , the coBRIM trial was utilized .
21-1	3788-3791	For	_	_	_	_
21-2	3792-3795	the	abstract[241]|abstract[242]	giv[241]|giv[242]	_	_
21-3	3796-3807	cobimetinib	abstract[241]|abstract[242]	giv[241]|giv[242]	_	_
21-4	3808-3812	plus	abstract[242]	giv[242]	_	_
21-5	3813-3824	vemurafenib	abstract[242]|abstract|abstract[244]	giv[242]|giv|giv[244]	coref|coref	22-19[253_244]|22-19[253_244]
21-6	3825-3836	combination	abstract[242]|abstract[244]	giv[242]|giv[244]	_	_
21-7	3837-3838	,	_	_	_	_
21-8	3839-3842	the	abstract[246]	giv[246]	_	_
21-9	3843-3849	coBRIM	abstract|abstract[246]	giv|giv[246]	_	_
21-10	3850-3855	trial	abstract[246]	giv[246]	_	_
21-11	3856-3859	was	_	_	_	_
21-12	3860-3868	utilized	_	_	_	_
21-13	3869-3870	.	_	_	_	_

#Text=The COLUMBUS study was utilized as a source of additional information for adverse events for the encorafenib plus binimetinib combination .
22-1	3871-3874	The	abstract[248]	new[248]	_	_
22-2	3875-3883	COLUMBUS	place|abstract[248]	giv|new[248]	_	_
22-3	3884-3889	study	abstract[248]	new[248]	_	_
22-4	3890-3893	was	_	_	_	_
22-5	3894-3902	utilized	_	_	_	_
22-6	3903-3905	as	_	_	_	_
22-7	3906-3907	a	_	_	_	_
22-8	3908-3914	source	_	_	_	_
22-9	3915-3917	of	_	_	_	_
22-10	3918-3928	additional	abstract[249]	giv[249]	_	_
22-11	3929-3940	information	abstract[249]	giv[249]	_	_
22-12	3941-3944	for	abstract[249]	giv[249]	_	_
22-13	3945-3952	adverse	abstract[249]|event[250]	giv[249]|new[250]	_	_
22-14	3953-3959	events	abstract[249]|event[250]	giv[249]|new[250]	_	_
22-15	3960-3963	for	abstract[249]|event[250]	giv[249]|new[250]	_	_
22-16	3964-3967	the	abstract[249]|event[250]|substance[251]	giv[249]|new[250]|giv[251]	_	_
22-17	3968-3979	encorafenib	abstract[249]|event[250]|substance[251]	giv[249]|new[250]|giv[251]	_	_
22-18	3980-3984	plus	abstract[249]|event[250]|substance[251]	giv[249]|new[250]|giv[251]	_	_
22-19	3985-3996	binimetinib	abstract[249]|event[250]|substance[251]|object|abstract[253]	giv[249]|new[250]|giv[251]|giv|giv[253]	_	_
22-20	3997-4008	combination	abstract[249]|event[250]|substance[251]|abstract[253]	giv[249]|new[250]|giv[251]|giv[253]	_	_
22-21	4009-4010	.	_	_	_	_
